The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
Eight new companies have joined The BioInnovation Institute’s (BII’s) Venture Lab acceleration program for early-stage companies, it was announced today (August 31).
More people are talking about mental illness than ever before. However, despite increased awareness, it remains one of the most neglected areas of public health globally, with research and quality of care lagging behind physical health conditions.
With more than 63 biopharma companies attending and 15 event partners sharing solutions, the 7th Annual IPF Summit being held in Boston next month (September 2023) is not to be missed.
Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.
CDMO, Sirio Europe, is launching two new softgels aimed at those who want to develop in the pharmaceutical consumer health space at this year’s CPHI in Barcelona.
STARLIMS, a company that provides enterprise informatics solutions has acquired Labstep, a research and development (R&D) electronic laboratory notebook (ELN).
Emerald Cloud Lab (ECL) was the world’s first highly automated cloud laboratory, was set up by two friends, Brian Frezza and D.J Kleinbaum who grew up together and joined forces after their PhDs to found the company.
Mahana Therapeutics announced last week (August 22) that it was entering into a multi-million dollar distribution and marketing partnership with the consumer health division of Bayer.
FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
The US Food and Drug Administration (FDA) has given orphan drug designation (ODD) to Redx’s Zelasudil for the potential treatment of idiopathic pulmonary fibrosis (IPF).
A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.
Integrated drug formulation and clinical trials company, BDD Pharma, will be expanding its phase appropriate development, manufacturing, and clinical testing services after a £2 million ($1.3 million) investment.
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers and shakers in the pharma industry. From Karuna Therapeutics to IO Biotech, we break down the key changes on the pharmaceutical job ladder.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
OSP discussed going beyond industry sponsors and how to support both patients and centers through clincal trial design with Erin Leckrone, senior director, clinical trials and Kathleen Kane, senior manager, clinical operations, at Be The Match BioTherapies....
The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.
Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.
LighthouseAI, a company that specializes in compliance solutions for the pharmaceutical supply chain, has announced a $2.25 million seed round, led by Healthy Ventures with participation from Bertelsmann Next.
Patients suffering from catheter-related bloodstream infections could be treated with Citius Pharmaceuticals antibiotic lock solution after it achieved 92 milestone events in its phase 3 trial.
Chronic hives could be treated effectively, conveniently, and rapidly after positive results from a clinical trial by Novartis produced positive top line results.
The first patient has been enrolled in a phase 3 clinical trial of leniolsib a treatment for a rare inherited condition affecting how the immune system works.
Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
OSP was fortunate enough to have an interesting discussion with Stephen Corson, who is a statistics manager at Phastar, a specialist biometrics CRO headquartered in the UK.
The first oral pill in the United States specifically for postpartum depression, a serious mental illness, has been approved by the US Food and Drug Administration (FDA).
At-risk families of patients diagnosed with motor neurone disease (MND), better known in the US as amyotrophic lateral sclerosis (ALS) will now have access to genetic sequencing thanks to a financial award from Innovate UK.
Dr. Susan Wood is CEO and president of VIDA Diagnostics. She has over 25 years of experience championing clinical intelligence solutions into routine clinical use.
PureTech Health plc has been awarded $11.4 million (£8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
